SNNC Sibannac, Inc.

OTC Pharmaceutical Preparations NV CIK: 0001313938
AI RATING
STRONG_SELL
85% Confidence

Investment Thesis

Sibannac is technically insolvent with negative stockholders equity of -396.1K and liabilities exceeding assets by 396K. The company generates minimal revenue (41K) while operating at catastrophic losses (net loss -103.3K), creating an acute liquidity crisis with current ratio of 0.03x indicating inability to meet obligations.

Strengths

Risks

  • ! Technical insolvency: negative stockholders equity (-396.1K) with liabilities exceeding total assets
  • ! Severe liquidity crisis with current ratio of 0.03x and negative operating cash flow (-7.0K)
  • ! Unsustainable business model generating 41K revenue against 103.3K net loss with negative gross margin of -90.8%

Key Metrics to Watch

Financial Metrics

Revenue
41.0K
Net Income
-103.3K
EPS (Diluted)
$0.00
Free Cash Flow
-7.0K
Total Assets
262.3K
Cash
12.3K

Profitability Ratios

Gross Margin -90.8%
Operating Margin -208.3%
Net Margin -251.8%
ROE N/A
ROA -39.4%
FCF Margin -17.0%

Balance Sheet & Liquidity

Current Ratio
0.03x
Quick Ratio
-0.01x
Debt/Equity
N/A
Debt/Assets
251.0%
Interest Coverage
-4.80x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-04-16T05:51:27.839868 | Data as of: 2017-02-28 | Powered by Claude AI